pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Oncology · news · pharmadog
← back to Oncology
News · Oncology
910
stories
15d
Why Big Pharma is chasing the industry’s most-powerful supercomputer
biopharma dive
15d
Is the biotech capital of the world moving?
stat
15d
A third clinic settles with DOJ over trans care
stat
15d
Latigo IPO raises nearly $350M for pain drug development
biopharma dive
15d
Ensoma sheds more staff, pauses preclinical programs to home in on lead gene therapy
fiercebiotech
15d
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
fiercebiotech
15d
Updated: BlossomHill, Latigo cap four-IPO week with combined $496M haul
endpoints
15d
This Week at FDA: Inspection reorg, acting CBER chief eyes IND reforms, and more
raps
15d
EMA issues updated guidance on shortage prevention plans ahead of legal deadline
raps
15d
Replimune rebounds to win FDA approval of melanoma drug
biopharma dive
15d
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
biospace
15d
STAT+: FDA approves Replimune melanoma drug previously rejected twice
stat
15d
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
fda press
16d
Chutes & Ladders—BioNTech brings in Sobi CEO
fiercebiotech
16d
Opinion: One year since Kennedy canceled mRNA vaccine projects, science shows how wrong he was
stat
16d
LifeMine raises $263M in mission to improve organ transplant aftercare
biospace
16d
CROs vs. biotechs: Finding the right fit
biospace
16d
The top 12 companies hiring in biopharma now
biospace
16d
Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
fiercebiotech
16d
Actimed gets back rights to wasting disease drug, ending $126M deal with Faraday
fiercebiotech
16d
FDA approves Moderna flu vaccine after spat with past agency leaders
endpoints
16d
Revolution Medicines preps for launching pancreatic cancer drug, ups 2026 expenses
endpoints
16d
Cardiac drug developer Braveheart banks more than $382M in IPO
biopharma dive
17d
Lilly confident in slow and steady Foundayo launch, as ex-US sales shine
biospace
17d
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
biopharma dive
17d
No deal between AstraZeneca and BMS, senior source insists: Reuters
biospace
17d
Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad
biospace
17d
Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts
biospace
17d
STAT+: Pharmalittle: We’re reading about a Medicare pilot and orphan drugs, Pfizer cutbacks, and more
stat
17d
Merger talks between AstraZeneca, Bristol Myers are off — report
endpoints
← prev
page 6 of 31
next →
